FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303983591> ?p ?o ?g. }

• W4303983591 endingPage "2" @default.
• W4303983591 startingPage "1" @default.
• W4303983591 abstract "Introduction: PET-guided treatment of newly diagnosed advanced stage (AS) classical Hodgkin Lymphoma (cHL) patients with eBEACOPP (escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procar-bazine, prednisone) achieves outstanding survival outcomes, but also causes relevant treatment-related morbidity (TRMB). CD30-targeted therapy with brentuximab vedotin (BV) has proven high efficacy and favorable tolerability in patients with cHL. In the HD21 study, we hypothesized that using BV to remodel the eBEACOPP regimen could further decrease TRMB while maintaining its high efficacy. Here, we report the final analysis of the TRMB endpoint. Methods: Adult patients ≤ 60 years of age with AS-cHL were included in this international randomized phase III trial. Patients were randomized in a 1:1 ratio to PET2-guided 4–6 cycles of either standard eBEACOPP or experimental BrECADD treatment (BV, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone). PET2 was assessed by blinded panel review (PP-2). Reduction of TRMB was the first part of the co-primary endpoint, whereas non-inferiority of progression-free survival (PFS) was the second part. TRMB was defined as any CTCAE grade 3 or 4 organ toxicity or grade 4 hematological toxicity (anemia, thrombocytopenia, infection) during treatment. TRMB was determined using the Cochran-Mantel-Haenszel method. Stratification factors included sex, age, IPS, and location of trial site. Categorical variables were compared using fisher’ s exact test. Exploratory analyses were performed for further safety outcome parameters. The trial was registered at clinicaltrials.gov (NCT02661503) and conducted according to ICH-GCP guidelines. Results: Between July 2016 and August 2020, we enrolled 1,500 patients from 9 countries. 1,470 patients are in the intention-to-treat (ITT) population (eBEACOPP n=732, BrECADD n=738). Baseline characteristics such as sex (male=56%), age (≤45 years=79%), IPS (0–2=54%), location (Europe=92%) and stage (III/IV=84%) were well balanced between treatment arms. As recommended by PP2, 59% of patients had 4 cycles and 41% received 6 cycles of therapy, without differences between treatment groups. TRMB was documented in 59% of patients in the eBEACOPP group (rel-risk, 1.41; 95% CI, 1.27–1.56, p<0.001) and 42% in the BrECADD group (rel-risk, 0.72; 95% CI, 0.65–0.79, p<0.001). The relative risk estimates remained stable among stratification factors. In the eBEACOPP group 52% of patients had hematological TRMB events compared to 31% in the BrECADD group (p<0.001). At least one red cell transfusion was given in 22% of patients in the eBEACOPP group and in 8% in the BrECADD group and at least one platelet transfusion in 13% and 6%, respectively. Severe leukopenia was observed in 94% and 87%, respectively. TRMB organ toxicity was documented in 17% of patients in the eBEACOPP group and 19% in the BrECADD group (p=0.455). Conclusion: The BrECADD regimen shows a significant and clinically relevant reduction of treatment-related morbidities compared to eBEACOPP in patients with newly diagnosed AS-cHL." @default.
• W4303983591 created "2022-10-10" @default.
• W4303983591 creator A5003056562 @default.
• W4303983591 creator A5012101254 @default.
• W4303983591 creator A5013171926 @default.
• W4303983591 creator A5020097248 @default.
• W4303983591 creator A5039994927 @default.
• W4303983591 creator A5041565323 @default.
• W4303983591 creator A5047622301 @default.
• W4303983591 creator A5049532038 @default.
• W4303983591 creator A5053252307 @default.
• W4303983591 creator A5055422099 @default.
• W4303983591 creator A5055817555 @default.
• W4303983591 creator A5056600574 @default.
• W4303983591 creator A5059188766 @default.
• W4303983591 creator A5061229750 @default.
• W4303983591 creator A5063668772 @default.
• W4303983591 creator A5064045994 @default.
• W4303983591 creator A5064132655 @default.
• W4303983591 creator A5065655150 @default.
• W4303983591 creator A5067716137 @default.
• W4303983591 creator A5068013617 @default.
• W4303983591 creator A5071228709 @default.
• W4303983591 creator A5073165908 @default.
• W4303983591 creator A5075117420 @default.
• W4303983591 creator A5076075055 @default.
• W4303983591 creator A5076077834 @default.
• W4303983591 creator A5076460303 @default.
• W4303983591 creator A5082867129 @default.
• W4303983591 creator A5083161940 @default.
• W4303983591 creator A5084849504 @default.
• W4303983591 creator A5086857861 @default.
• W4303983591 date "2022-10-01" @default.
• W4303983591 modified "2023-10-12" @default.
• W4303983591 title "T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group" @default.
• W4303983591 doi "https://doi.org/10.1097/01.hs9.0000890576.23258.1c" @default.
• W4303983591 hasPublicationYear "2022" @default.
• W4303983591 type Work @default.
• W4303983591 citedByCount "0" @default.
• W4303983591 crossrefType "journal-article" @default.
• W4303983591 hasAuthorship W4303983591A5003056562 @default.
• W4303983591 hasAuthorship W4303983591A5012101254 @default.
• W4303983591 hasAuthorship W4303983591A5013171926 @default.
• W4303983591 hasAuthorship W4303983591A5020097248 @default.
• W4303983591 hasAuthorship W4303983591A5039994927 @default.
• W4303983591 hasAuthorship W4303983591A5041565323 @default.
• W4303983591 hasAuthorship W4303983591A5047622301 @default.
• W4303983591 hasAuthorship W4303983591A5049532038 @default.
• W4303983591 hasAuthorship W4303983591A5053252307 @default.
• W4303983591 hasAuthorship W4303983591A5055422099 @default.
• W4303983591 hasAuthorship W4303983591A5055817555 @default.
• W4303983591 hasAuthorship W4303983591A5056600574 @default.
• W4303983591 hasAuthorship W4303983591A5059188766 @default.
• W4303983591 hasAuthorship W4303983591A5061229750 @default.
• W4303983591 hasAuthorship W4303983591A5063668772 @default.
• W4303983591 hasAuthorship W4303983591A5064045994 @default.
• W4303983591 hasAuthorship W4303983591A5064132655 @default.
• W4303983591 hasAuthorship W4303983591A5065655150 @default.
• W4303983591 hasAuthorship W4303983591A5067716137 @default.
• W4303983591 hasAuthorship W4303983591A5068013617 @default.
• W4303983591 hasAuthorship W4303983591A5071228709 @default.
• W4303983591 hasAuthorship W4303983591A5073165908 @default.
• W4303983591 hasAuthorship W4303983591A5075117420 @default.
• W4303983591 hasAuthorship W4303983591A5076075055 @default.
• W4303983591 hasAuthorship W4303983591A5076077834 @default.
• W4303983591 hasAuthorship W4303983591A5076460303 @default.
• W4303983591 hasAuthorship W4303983591A5082867129 @default.
• W4303983591 hasAuthorship W4303983591A5083161940 @default.
• W4303983591 hasAuthorship W4303983591A5084849504 @default.
• W4303983591 hasAuthorship W4303983591A5086857861 @default.
• W4303983591 hasBestOaLocation W43039835911 @default.
• W4303983591 hasConcept C126322002 @default.
• W4303983591 hasConcept C141071460 @default.
• W4303983591 hasConcept C143998085 @default.
• W4303983591 hasConcept C168563851 @default.
• W4303983591 hasConcept C203092338 @default.
• W4303983591 hasConcept C2776694085 @default.
• W4303983591 hasConcept C2776755627 @default.
• W4303983591 hasConcept C2778119113 @default.
• W4303983591 hasConcept C2778191690 @default.
• W4303983591 hasConcept C2779338263 @default.
• W4303983591 hasConcept C2779429289 @default.
• W4303983591 hasConcept C2780964509 @default.
• W4303983591 hasConcept C2781413609 @default.
• W4303983591 hasConcept C2992779791 @default.
• W4303983591 hasConcept C71924100 @default.
• W4303983591 hasConceptScore W4303983591C126322002 @default.
• W4303983591 hasConceptScore W4303983591C141071460 @default.
• W4303983591 hasConceptScore W4303983591C143998085 @default.
• W4303983591 hasConceptScore W4303983591C168563851 @default.
• W4303983591 hasConceptScore W4303983591C203092338 @default.
• W4303983591 hasConceptScore W4303983591C2776694085 @default.
• W4303983591 hasConceptScore W4303983591C2776755627 @default.
• W4303983591 hasConceptScore W4303983591C2778119113 @default.
• W4303983591 hasConceptScore W4303983591C2778191690 @default.
• W4303983591 hasConceptScore W4303983591C2779338263 @default.
• W4303983591 hasConceptScore W4303983591C2779429289 @default.
• W4303983591 hasConceptScore W4303983591C2780964509 @default.

• next